頭頸部癌免疫療法のエッセンス
Author:
Affiliation:
1. 東京医科大学耳鼻咽喉科・頭頸部外科学分野
Publisher
Oto-Rhino-Laryngological Society of Japan, Inc.
Link
https://www.jstage.jst.go.jp/article/jibiinkotokeibu/125/7/125_1062/_pdf
Reference18 articles.
1. 1) 塚原清彰: PD-1 阻害剤 (頭頸部癌). 日気食会報 2020; 71: 338-340.
2. 2) Lee NY, Ferris RL, Psyrri A, et al: Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021; 22: 450-462.
3. 3) Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
4. 4) Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
5. 5) Sato H, Tsukahara K, Okamoto I, et al: Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. Acta Otolaryngol 2019; 139: 201-205.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Utility of Access® in head and neck cancer database management and extraction;Toukeibu Gan;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3